Palovarotene

Brand names: Sohonos · Active ingredient: Palovarotene

In short: SOHONOS is indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP).

Forms & strengthsSOHONOS is available in 4 strengths as an opaque white elongated size "0" hard-gelatin capsule, containing white to off-white powder. Table 4 shows capsules' strengths and imprints. Strength (mg) | Imprint 1 | PVO 1 1.5 | PVO 1.5 5 | PVO 5 10 | PVO 10
LabelIpsen Biopharmaceuticals, Inc.
Label updatedSep 28, 2026

What is Palovarotene used for?

SOHONOS is indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP).

âš  Boxed warning (FDA's strongest warning)

Embryo-Fetal Toxicity

SOHONOS is contraindicated in pregnancy. SOHONOS may cause fetal harm. Because of the risk of teratogenicity and to minimize fetal exposure, SOHONOS is to be administered only if conditions for pregnancy prevention are met .

Premature Epiphyseal Closure

Premature epiphyseal closure occurs in growing pediatric patients treated with SOHONOS, close monitoring is recommended .

Palovarotene dosage

For females of reproductive potential, obtain a negative pregnancy test within one week prior to initiating and periodically during SOHONOS therapy. If pregnancy occurs, stop SOHONOS treatment immediately and refer patient to an obstetrician/gynecologist experienced in reproductive toxicity. .

Dosage Overview

Take SOHONOS with food preferably at the same time each day . The recommended dosing for SOHONOS includes a chronic daily dosage (daily dose) which can then be modified/increased in the event of FOP flare-up symptoms (flare-up dose).

Initiate flare-up treatment at the onset of the first symptom indicative of a FOP flare-up or substantial high-risk traumatic event likely to lead to a flare-up (e.g., surgery, intramuscular immunization, mandibular blocks for dental procedures, muscle fatigue, blunt muscle trauma from bumps, bruises, falls, or influenza-like viral illnesses). Symptoms of a FOP flare-up typically include but are not limited to localized pain, soft tissue swelling/inflammation, redness, warmth, decreased joint range of motion, and stiffness.

Multiple lower strength capsules (1 mg, 1.5 mg or 5 mg capsules) should not be substituted for a single 10 mg capsule .

Recommended Dosage for Adults and Pediatric Patients 14 Years and Older

Daily Dose: The recommended SOHONOS daily dosage for adults and pediatric patients 14 years and older is 5 mg daily. Stop daily dosing when flare-up dosing begins.

Flare-up Dose:

The recommended SOHONOS flare-up dosage for adults and pediatric patients 14 years and older is 20 mg daily for 4 weeks, followed by 10 mg daily for 8 weeks (for a total of 12 weeks of flare-up treatment), even if symptoms resolve earlier, then return to daily dosing of 5 mg.

If during the course of flare-up treatment, the patient experiences marked worsening of the original flare-up site or another flare-up at a new location, restart the 12-week flare-up dosing at 20 mg daily.

For flare-up symptoms that have not resolved at the end of the 12-week period, the 10 mg daily dosage may be extended in 4-week intervals and continued until the flare-up symptoms resolve. If new flare-up symptoms occur after the 5 mg daily dosing is resumed, flare-up dosing may be restarted.

Recommended Dosage for Pediatric Patients Aged 8 to 13 Years for Females and Aged 10 to 13 Years for Males

Daily Dose: The recommended SOHONOS daily dosage for patients under 14 years of age is weight-based, ranging from 2.5 mg to 5 mg daily . Stop daily dosing when flare-up dosing begins.

Flare-up Dose:

The recommended flare-up SOHONOS dosage for patients under 14 years of age is weight-based . …

How to take Palovarotene — instructions & advice from the label

Advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide).

Embryo-Fetal Toxicity:

Advise patients that SOHONOS can cause fetal harm and is contraindicated during pregnancy. Advise patients to verify that they are not pregnant prior to initiating and periodically during SOHONOS treatment as well as one month after treatment discontinuation [see Contraindications (4), Warnings and Precautions (5.1), and Use in Specific Populations (8.3)].

Advise females of reproductive potential that they must avoid pregnancy while taking SOHONOS and for at least one month following discontinuation of therapy.

Advise females of childbearing potential to use at least one highly effective method of contraception (i.e. IUD) or two effective methods (i.e. combined hormonal contraception in combination with another method of contraception such as a barrier method) during treatment with SOHONOS .

Instruct patients to immediately stop taking SOHONOS if she becomes pregnant while taking SOHONOS and to rapidly consult her healthcare provider if there is a risk of pregnancy or if she might be pregnant. …

Warnings & precautions

Do not take this medicine if: SOHONOS is contraindicated in the following patients:

During Pregnancy .

A history of allergy or hypersensitivity to retinoids, or to any component of SOHONOS. Anaphylaxis and other allergic reactions have occurred with other retinoids. .

SOHONOS can cause fetal harm and is contraindicated during pregnancy. SOHONOS is a member of the retinoid class of drugs which is associated with birth defects in humans. In animal reproduction studies, palovarotene administered orally to pregnant rats during organogenesis was teratogenic and caused fetal malformations typical of retinoids including cleft palate, misshapen skull bones, and shortening of the long bones at clinically relevant exposures.

For females of reproductive potential, verify that the patient is not pregnant prior to initiating treatment, periodically during the course of therapy and one month after treatment discontinuation. Advise females of reproductive potential to use an effective method of contraception at least one month prior to treatment, during treatment with SOHONOS and for 1 month after the last dose . If a pregnancy occurs during SOHONOS treatment, discontinue treatment immediately and refer the patient to an obstetrician/gynecologist experienced in reproductive toxicity for further evaluation and counseling.

Patients should be informed not to donate blood during SOHONOS therapy and for 1 week following discontinuation because the blood might be given to a pregnant patient whose fetus must not be exposed to palovarotene.

SOHONOS can cause irreversible premature epiphyseal closure and potential adverse effects on growth. In clinical studies, premature epiphyseal closure occurred with SOHONOS treatment in growing pediatric patients with FOP .

Monitoring of linear growth is recommended in growing pediatric patients . …

Palovarotene side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Premature Epiphyseal Closure in Growing Pediatric Patients

Mucocutaneous Adverse Reactions

Metabolic Bone Disorders

Psychiatric Disorders

Night Blindness

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of SOHONOS was evaluated in clinical studies that enrolled a total of 164 subjects with FOP, including 139 subjects in the indicated population of ages 8 years and above for females and 10 years and above for males (8/10 years and older). Most of these subjects received open label treatment with the chronic daily/flare-up regimen, consisting of 5 mg daily dosage of oral SOHONOS with a 20/10 mg dosage as needed for 12 weeks at the time of flare-up (4 weeks of 20 mg once daily followed by 10 mg once daily for 8 weeks), with all doses reduced by weight in subjects who were less than 90% skeletally mature. The mean duration of exposure was 79 weeks for chronic dosing (N=131 subjects) and 35 weeks for flare-up dosing (N=105 subjects). The mean age of these subjects was 19 years (range 8 to 61 years); 51% were male. …

Drug interactions

Clinically significant drug interactions affecting the exposure of SOHONOS are listed in Table 6.

Strong CYP3A Inhibitors

Clinical Impact | Co-administration of SOHONOS with strong CYP3A4 inhibitors increased the exposures of palovarotene , which may increase the risk of SOHONOS adverse reactions.

Prevention or Management | Avoid concomitant use of a strong CYP3A4 inhibitor during SOHONOS treatment .

Moderate CYP3A Inhibitors

Clinical Impact | Co-administration of SOHONOS with moderate CYP3A4 inhibitors may increase the exposure of palovarotene , which may increase the risk of SOHONOS adverse reactions.

Prevention or Management | Avoid concomitant use of a moderate CYP3A4 inhibitor with SOHONOS, if possible. If co-administration will occur, reduce the SOHONOS dose by half when co-administered with moderate CYP3A inhibitors .

Strong CYP3A Inducers

Clinical Impact | Co-administration of SOHONOS with strong CYP3A4 inducers decreased the exposure of palovarotene , which may reduce the effectiveness of SOHONOS.

Prevention or Management | Avoid concomitant use of strong CYP3A4 inducers with SOHONOS. . …

About this medicine

Palovarotene is an orally bioavailable retinoid that acts as a retinoic acid receptor (RAR) agonist with particular selectivity at the gamma subtype of RAR. Palovarotene is chemically described as 4-[(E)-2-(5,5,8,8-tetramethyl-3-pyrazol-1-ylmethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-benzoic acid with an empirical formula of C27H30N2O2 and has a molecular weight of 414.54 g/mol.

The structural formula is represented below:

SOHONOS capsules are supplied in 1 mg, 1.5 mg, 5 mg and 10 mg strengths. Each capsule contains palovarotene as the active ingredient and the following inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium lauryl sulfate. The capsule consists of gelatin and titanium dioxide. The black printing ink consists of black iron oxide, potassium hydroxide, propylene glycol and Shellac. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 67dce406-7cc4-4d66-92de-ad18b6df0625. Read the full official label on DailyMed.